- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Some hope remains this year for Medicare bill
There is still hope for a Medicare "giveback" bill before Congress adjourns for good this year, and the possibility of a broader Medicare drug benefit than the discount card just announced by the Bush administration could be the best last chance to get this done.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
LEVEL UP Trial Sets New Benchmark for Atopic Dermatitis Treatment
How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD
Expanding Topical Non-Steroidal Options in Atopic Dermatitis to Reduce Chronic Steroid Use
Understanding the Role of OX40 in Next-Generation Eczema Therapies
Jonathan Silverberg, MD, PhD, MPH on Keeping Up With Rapid AD Developments
The Vicious Cycle of Itch, Stress, and Sleep Loss
Christopher Bunick, MD, PhD, Previews RAD 2025: Raising the Bar in Atopic Dermatitis Care
Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments
Related Content
